<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03281200</url>
  </required_header>
  <id_info>
    <org_study_id>1199-0295</org_study_id>
    <nct_id>NCT03281200</nct_id>
  </id_info>
  <brief_title>Chart Review Study to Describe the Clinical Profile of Idiopathic Pulmonary Fibrosis (IPF) Patients Treated With Nintedanib (OFEV®) in Real-world Practice in Spain</brief_title>
  <official_title>A Multicentre, Retrospective Chart Review Study to Describe the Clinical Profile of Idiopathic Pulmonary Fibrosis (IPF) Patients Treated With Nintedanib (OFEV®) in Real-world Practice in Spain.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study has been designed to characterize IPF patients treated with nintedanib
      (OFEV®), at time of treatment initiation, with respect to their clinical profile based on
      real-world data from January 2016 in Spanish Pulmonology Services.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 24, 2017</start_date>
  <completion_date type="Anticipated">May 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>distribution of patients across different lung function categories (%FVC and DLCO serving as surrogate markers for IPF severity) of IPF patients at the time of treatment initiation with nintedanib (OFEV®) in routine clinical practice</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>frequency of each method of diagnosis</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean duration of the disease from diagnosis to treatment initiation</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>frequency of patients with associated emphysema</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>frequency of patients with UIP pattern (according to international guideline, Raghu et al. 2011)</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OFEV® treatment initiation date of each dose</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OFEV® treatment initiation frequency of each dose</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient demographics (age, male and female, race)</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examination ( height, weight, BMI, mean distance of the 6 minutes walking</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>smoking status (current smokers, former smokers and never smokers)</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>breathlessness grade mMRC</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>concomitant medication (active substance, dose, initiation date, indication)</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of exacerbations due to IPF in the previous year</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean frequency of exacerbations due to IPF in the previous year</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Actual">173</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>Anatomical main group:</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Therapeutic subgroup</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Pharmacological subgroup</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemical subgroup</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemical substance</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L - Antineoplastic and immunomodulating agents</intervention_name>
    <description>L - Antineoplastic and immunomodulating agents</description>
    <arm_group_label>Anatomical main group:</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L01 - Antineoplastic agents</intervention_name>
    <description>L01 - Antineoplastic agents</description>
    <arm_group_label>Therapeutic subgroup</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L01X - Other antineoplastic agents</intervention_name>
    <description>L01X - Other antineoplastic agents</description>
    <arm_group_label>Pharmacological subgroup</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L01XE - Protein kinase inhibitors</intervention_name>
    <description>L01XE - Protein kinase inhibitors</description>
    <arm_group_label>Chemical subgroup</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L01XE31 - Nintedanib</intervention_name>
    <description>L01XE31 - Nintedanib</description>
    <arm_group_label>Chemical substance</arm_group_label>
    <other_name>OVEF</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Approximately 175 IPF patients from 35 Pulmonology Services in Spain are planned to be
        included in the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient is at least 18 years old

          -  The patient has IPF diagnosis according to most recent ATS/ERS/JRS/ALAT IPF guideline
             for diagnosis and management [5]

          -  The patient newly initiated treatment with nintedanib (OFEV®) since 01 January 2016 up
             to end of data collection date, according to the approved local SmPC. -

        Exclusion Criteria:

        - Patients treated with nintedanib within a clinical trial or named-patient program or with
        any prior treatment of nintedanib.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dynamic solutions</name>
      <address>
        <city>Barcelona</city>
        <zip>08029</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2017</study_first_submitted>
  <study_first_submitted_qc>September 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2017</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nintedanib</mesh_term>
    <mesh_term>Antineoplastic Agents</mesh_term>
    <mesh_term>Protein Kinase Inhibitors</mesh_term>
    <mesh_term>Immunologic Factors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

